Latest news with #Mankind
News18
2 days ago
- Entertainment
- News18
'We Will Win Again': Astromancer Bharat J. Mehra's Message of Positivity Amid Global Anxiety
Last Updated: In a heartfelt video, Bharat J Mehra urges people to overcome fear and embrace hope, reminding us all to trust life, stay resilient, and face uncertain times with kindness In a world grappling with uncertainty and unsettling predictions, astromancer-entrepreneur Bharat J. Mehra has released a powerful video urging calm, clarity, and collective optimism. Known for his grounded take on astrology and wellness, Mehra's message is clear: don't panic, stay hopeful, and trust the process of life. Amid rising chatter about potential global catastrophes from wars and floods to epidemics and plane crashes, Mehra acknowledges the anxiety these astrological predictions can trigger. 'I have come out with this video to calm down agitated nerves, destress you all from the impending scare of so many disasters in the waiting—or so has been predicted by so many learned people who follow the beautiful, exact science called astrology." For him, the focus lies in changing the emotional climate, not feeding fear. 'The need of the hour is to spread positivity which is where I come in." Though he humbly mentions that he has 'a little knowledge about planets and their side effects," Mehra emphasizes the importance of emotional resilience. 'We as a race, as Mankind need to take a chill pill. We fought Covid earlier. We shall do it again." 'We Will Do It! We Will Win – Again & Again & Again!" he declares emphatically in the video, setting the tone for a stirring message meant to uplift and de-stress his audience. Calling for individual empowerment over mass fear, he states, 'Mass predictions are not the answer. We all have different kundlis, me and my manager or driver for that matter cannot have the same chart!" Instead, he urges people to anchor themselves in inner strength, karma, and faith. 'The whole world needs to slow down, believe in the goodness of Mother Nature, trust in our own Karmas and the blessings of our elders, and learn to just trust life itself." Ending on a heartfelt note, Mehra signs off with a message that feels both grounding and inspiring, 'Eat, pray and love ❤️ and yes be kind. It costs nothing!!" With that, he promises to return with a more detailed video soon, continuing his mission to be a 'Friend, Philosopher and Guide" to those navigating today's turbulent times. Who is Bharat J Mehra? Bharat J Mehra, astromancer, founder of Bharat Mehra Strategies, is a dynamic entrepreneur and passionate humanitarian whose work bridges the worlds of business and social service. Renowned for his insightful predictions, he advises prominent figures like Ajay Piramal and Anant Ambani, and comfortably moves within elite circles including celebrities like Shah Rukh Khan. However, his true dedication lies in serving Maharashtra's tribal and marginalized populations, a mission he has pursued for over 25 years. As the head of the Radha Meera Charitable Trust and the Krishnakali Navgrah Mandir Trust, Bharat leads initiatives that provide free services aimed at improving both mental and physical health. His philanthropic focus revolves around fighting hunger, improving healthcare, promoting education, and empowering women, all with the goal of fostering self-sufficient and sustainable communities. His vision aligns closely with the developmental priorities championed by Prime Minister Narendra Modi, emphasizing grassroots progress and inclusive growth. Over the last five years, Bharat's efforts have positively impacted more than 250,000 people—delivering daily meals to 2,000 villagers, offering healthcare and medicines to thousands, supporting hundreds of students with education, and providing vocational training to women. With ambitions to broaden his outreach nationwide, Bharat J Mehra remains committed to creating empowered and dignified communities across India. About the Author Swati Chaturvedi Swati Chaturvedi, a seasoned media and journalism aficionado with over 10 years of expertise, is not just a storyteller; she's a weaver of wit and wisdom in the digital landscape. As a key figure in News18 More Watch CNN-News18 here. The News18 Lifestyle section brings you the latest on health, fashion, travel, food, and culture — with wellness tips, celebrity style, travel inspiration, and recipes. Also Download the News18 App to stay updated!
Mint
27-05-2025
- Business
- Mint
Mankind to expand gastro, derma presence, says MD Rajeev Juneja
Mankind Pharma is focused on expanding its presence in the gastrointestinal and dermatology segments this year, as it looks at expanding its presence in the chronic segments, managing director Rajeev Juneja toldMintin an interview. 'We are not great in the gastro [segment]...we have decided that we are supposed to work a lot in gastro because it has become semi-chronic, and our inclination is towards the chronic side," Juneja said, adding thatgastro in India is one of the fastest-growing segments. 'Along with this, we are working on derma as well," he said. The gastro segment grew 7.3% year on year in April, according to pharma intelligence platform Pharmarack. Further, Mankind is developing a novel anti-obesity and diabetes drug in-house. The drug candidate, GRP119, is currently in phase 2 trials in Australia, and Juneja said that results are expected in the next six to nine months. In FY25, Mankind signed a non-exclusive patent licensing agreement with Takeda Pharmaceuticals to commercialise its novel drug Vonoprazan, to treat Gastroesophageal Reflux Disease (GERD). Also Read: Sun Pharma to ramp up growth-boosting specialty portfolio in FY26 Juneja said that the company is evaluating all options to increase its presence in these therapy areas, including in-licensing products from innovators or small acquisitions. 'No past strategy can be guaranteed for future success. So we need to apply our mind and try to bring some kind of differentiation in whatever we do," said Juneja. 'The point is that once we decide that our intention is that we are supposed to be good on the gastro side, we start searching for avenues, we start searching for people, we start searching for products," he said. The company will also continue to strengthen its leadership in the women's health segment, which received a boost last year through its acquisition of Bharat Serum and Vaccines (BSV). With its foundation strengthened in FY25, Mankind aims to grow 1.2 to 1.3 times the Indian pharmaceutical market. Juneja said this will be driven by its focus on its chronic domestic formulations portfolio. Juneja said the focus is also on growing larger brands, from the current ₹50 crore to ₹100 crore brands for products to ₹500 crore brands. 'This is the strategy we basically want to pursue in future, because we have seen that once you create that kind of a brand, that's a very big entry barrier," he added. BSV acquisition Mankind is on track with the integration of BSV, which it acquired for ₹13,768 crore in October 2024. The integration will be funded through a mix of internal accruals and external debt. Juneja said the company focused on removing the 'extra flab" and bringing in the right talent for the acquired entity in FY25. This year, he expects 18-20% growth from the BSV portfolio. The goal is to increase the reach and awareness of BSV's niche super-speciality products. BSV is working on two biosimilars, the company's investor presentation highlighted, although Juneja declined to share more details on the BSV pipeline. Also Read: Emcure Pharmaceuticals to expand gynaecology, derma portfolio for India market in FY26 Vishal Manchanda, senior vice president of Institutional Equities at Systematix Group, toldMintthat BSV's platform and skillset for making recombinant drugs (created by inserting genes from one species into a host species) can be leveraged to make biosimilars. Select companies in India, including Biocon, are skilled at the recombinant process. However, Manchanda pointed out that Mankind has the potential to scale this up meaningfully. Innovation push 'If you're a pharma company, naturally, you gain respect once you have great R&D," Juneja said. 'We started our own R&D in Mankind 13-14 years back…going forward, we'll be putting a bit more money in the R&D side…our R&D expenses will increase because that would be the future need as well." 'We wish to become a bigger company…our dream is to become India's number one company on the domestic side," Juneja said, adding that 'we need to have certain innovative products, and we are working for that". Mankind's focus on innovation and speciality segments comes as the Indian pharmaceutical market has become more crowded. Most segments already have established market leaders. '…the promoters are realising that there is a challenge to growth. And they know the space they have been playing in is now kind of difficult to expand from where they are, meaningfully expand from where they are. So I think Mankind promoters being extremely committed to India business, they are also kind of prepared on how to take this forward," Manchanda said. 'What they are actually looking for is a bigger avenue to build growth on," he added, referring to Mankind's BSV acquisition. Internal corrections Mankind undertook several internal correction initiatives in the last year, including leadership changes and improving synergies between its divisions, Juneja said. Also Read: Zydus bets big on vaccines and medtech 'If you look at the history of Mankind, in 30 years, we have become the fourth largest company," Juneja said, adding that for any company growing very fast, there comes a time when growth plateaus. 'But once you bring commercial excellence, you bring people from outside…a number of flaws can come in front of you, and you have two choices: Either to remove those flaws gradually without affecting your sales and profit and growth, or second, do it immediately," Juneja said. 'We belong to the second category, and we decided that by March 2025, we'll clean up Mankind from every side," he added.
&w=3840&q=100)
Business Standard
22-05-2025
- Business
- Business Standard
Mankind Pharma shares slide 3% as Q4 profit declines; details here
Shares of Mankind Pharma dropped over 3 per cent on Thursday as the company reported a 10 per cent fall in consolidated net profit for the March quarter of 2024-25 (Q4 FY25). The Delhi-based pharma major's stock fell as much as 3.22 per cent during the day to ₹2,450 per share, the biggest intraday fall since May 2 this year. The stock pared losses to trade 2.1 per cent lower at ₹2,478 apiece, compared to a 1 per cent decline in Nifty 50 as of 9:32 AM. Shares of the company extended losses to their fourth day and have fallen over 6 per cent from their recent highs of ₹2,610, which it hit earlier this month. The counter has fallen 14 per cent this year, compared to a 3.7 per cent advance in the benchmark Nifty 50. Mankind Pharma has a total market capitalisation of ₹1.01 trillion, according to BSE data. Mankind Pharma Q4FY25 results Mankind Pharma posted a 10 per cent fall in consolidated net profit Q4 FY25 at ₹424.65 crore from ₹476.59 crore in the same period last financial year. The pharma company's revenue from operations rose to ₹3,079 crore in Q4, a 27 per cent year-on-year (Y-o-Y) surge from ₹2,422 crore. At the operating level, Mankind's earnings before interest, tax, depreciation, and amortisation (Ebitda) rose to ₹686 crore, with an Ebitda margin of 22.3 per cent in the March quarter. This compares to ₹589 crore and 24.3 per cent, respectively, in the same period last financial year. The company reported that its domestic business revenues witnessed Y-o-Y growth of 18 per cent to ₹2,544 crore in the fourth quarter from ₹2,155 crore in Q4 FY24. It added that this growth was partially supported by continued outperformance in the chronic segment, at 1.3 times the Indian pharma market. Mankind Pharma management commentary Rajeev Juneja, vice-chairman (VC) and managing director (MD), said the company has achieved a healthy revenue growth in Q4. This was driven by strong growth in chronic therapies, recovery in the consumer segment and consolidation of Bharat Serums and Vaccines (BSV), he added. 'Recent key launches like Empagliflozin, Inclisiran and Vonoprazan were among the top five in their respective categories,' the company said in its investor presentation. About Mankind Pharma The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations and chronic therapeutic areas across as well as several consumer healthcare products. It is present in several acute and chronic therapeutic areas in India, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS vitamins /minerals/nutrients and respiratory.
&w=3840&q=100)
Business Standard
21-05-2025
- Business
- Business Standard
Mankind Pharma Q4: Profit drops 10%, revenue up 27% on domestic growth
Delhi-based Mankind Pharma on Wednesday reported a 10 per cent fall in consolidated net profit for the March quarter of 2024-25 (Q4 FY25) at ₹424.65 crore from ₹476.59 crore in the same period last financial year. Mankind's revenue from operations rose to ₹3,079 crore in Q4, a 27 per cent year-on-year (Y-o-Y) surge from ₹2,422 crore. At the operating level, Mankind's earnings before interest, tax, depreciation, and amortisation (Ebitda) rose to ₹686 crore, with an Ebitda margin of 22.3 per cent in the March quarter. This compares to ₹589 crore and 24.3 per cent, respectively, in the same period last financial year. Commenting on the results, Rajeev Juneja, vice-chairman (VC) and managing director (MD), said the company has achieved a healthy revenue growth in Q4. This was driven by strong growth in chronic therapies, recovery in the consumer segment and consolidation of Bharat Serums and Vaccines (BSV), he added. According to the company, its share in the domestic market increased from 4.4 per cent in March 2024 to 4.8 per cent as of March 2025. It was on account of BSV acquisition and leadership in the gynaecology segment. Mankind had completed the acquisition of 100 per cent stake in BSV for ₹13,768 crore in October 2024. The company reported that its domestic business revenues witnessed Y-o-Y growth of 18 per cent to ₹2,544 crore in the fourth quarter from ₹2,155 crore in Q4 FY24. 'Recent key launches like Empagliflozin, Inclisiran and Vonoprazan were among the top five in their respective categories,' the company said in its investor presentation. Mankind's consumer healthcare segment also reported a revenue growth of 14 per cent in Q4. The export business witnessed a growth of 100 per cent in the March quarter. It was driven by an increase in the base business and launches in the past one-two years, among others. The company declared its results after market hours. On Wednesday, Mankind Pharma's share went down marginally by 0.69 per cent, ending the day's trade at ₹2,533.03 on the BSE.
Time of India
28-04-2025
- Entertainment
- Time of India
Top 5 best managers in WWE History
Image via WWE In WWE's history, managers have played a crucial role in shaping the careers of some of the biggest superstars. Whether it was by cutting unforgettable promos, masterminding heel turns, or simply offering an imposing ringside presence, the best managers left an unforgettable memory on the industry. Here's a look at the top five who stood out the most. 5. Paul Bearer Few managers understood their characters better than Paul Bearer. With his haunting voice and fantastic persona, Bearer perfectly complemented The Undertaker, Kane, and Mankind. His ability to create fear and suspense added a new dimension to the supernatural storylines of WWE's New Generation Era. Whether carrying the funerary urn or plotting revenge against his former allies, Bearer's intelligence and psychological games made him unforgettable. 4. Freddie Blassie 'Classy' Freddie Blassie brought street-smart wisdom to his managerial career after retiring from the ring. Blassie's association with villains like The Iron Sheik, Kamala, and King Kong Bundy elevated their careers in a period when foreign heel gimmicks dominated. His sharp mind and unapologetic behaviour set the blueprint for what a manager could achieve in the early days of WWE. 3. Bobby Heenan Bobby Heenan's nickname, 'The Brain,' wasn't just for show. Heenan expertly manipulated situations to favor his clients, which included legends like Andre the Giant, Rick Rude, and Mr. Perfect. His managerial stable, The Heenan Family, was one of the most formidable forces in WWE. Whether distracting referees or cutting razor-sharp promos, Heenan's contributions to WWE's golden era remain unmatched. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas For Sale in Dubai Might Surprise You Villas In Dubai | Search Ads View Deals Undo 2. Jimmy Hart Known for his trademark megaphone and flashy jackets, Jimmy Hart was a relentless force during WWE's 1980s boom. Hart managed multiple iconic acts like the Hart Foundation, Honky Tonk Man, and Money Inc. His ability to generate heat for heels and occasionally pivot to managing babyfaces like Hulk Hogan showcased his versatile brilliance. 1. Paul Heyman Paul Heyman has continuously reinvented himself across eras, managing champions like Brock Lesnar, CM Punk, and Roman Reigns. Heyman's deep understanding of storytelling and character work has made him a genius strategist. His alliances with Roman Reigns and Seth Rollins have further solidified his reputation as perhaps the smartest man behind the mic in WWE history. While wrestlers often get the spotlight, these managers played just as important a role in WWE's success stories. They crafted narratives, enhanced performances, and created unforgettable moments that still resonate with fans today. As WWE evolves, the legacy of these iconic managers continues to inspire a new generation of characters looking to make their mark both inside and outside the ring.
